Compugen Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CGEN Nasdaq 2830 cgen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Compugen Ltd.

BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates - Nov 2nd, 2026 2:55 pm
Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026 - Oct 26th, 2026 5:00 am
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference - Oct 6th, 2026 5:00 am
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets - Oct 5th, 2026 3:02 pm
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026 - Sep 22nd, 2026 5:00 am
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference - Sep 8th, 2026 5:00 am
All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy - Aug 31st, 2026 10:00 am
Are Medical Stocks Lagging Compugen (CGEN) This Year? - Aug 21st, 2026 7:40 am
Compugen Ltd (CGEN) (Q2 2026) Earnings Call Highlights: Advancing COM701 with Strong Cash ... - Aug 5th, 2026 7:01 pm
Compugen Ltd. Q2 2026 Earnings Call Summary - Aug 4th, 2026 6:30 am
Compugen Q2 Earnings Call Highlights - Aug 3rd, 2026 8:04 am
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates - Aug 3rd, 2026 6:05 am
Compugen Reports Second Quarter 2026 Results - Aug 3rd, 2026 5:00 am
Compugen to Participate in BTIG Biotechnology Conference 2026 - Jul 21st, 2026 5:00 am
Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026 - Jul 20th, 2026 5:00 am
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress - Jun 18th, 2026 5:00 am
Compugen (CGEN) Stock Faces Mixed Analyst Target Changes After Cautious Valuation Revisions - Jun 17th, 2026 10:39 pm
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 - Jun 11th, 2026 5:00 am
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development - Jun 8th, 2026 5:00 am